Veeva and Roche Partnership: Veeva (VEEV) has announced that Roche Pharma (RHHBY) will implement Vault CRM globally, marking the tenth signed commitment and aligning with management's previous hints during the Q3 call.
Market Sentiment and Expectations: Despite initial assumptions about migration expectations being factored into the stock, negative feedback regarding Veeva retaining only 14 of the top 20 clients indicates ongoing concerns in the market.
Significance of the Deal: The global roll-out of Vault CRM for Roche suggests a significant and expansive deal for Veeva, countering investor expectations that Roche would switch to Salesforce due to its existing relationship with IQVIA.
Investment Outlook: Oppenheimer maintains an Outperform rating on Veeva, setting a price target of $325, viewing the Roche transaction as a positive shift in expectations and sentiment for the company.
Wall Street analysts forecast VEEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VEEV is 317.10 USD with a low forecast of 222.00 USD and a high forecast of 380.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23 Analyst Rating
Wall Street analysts forecast VEEV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VEEV is 317.10 USD with a low forecast of 222.00 USD and a high forecast of 380.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 225.280
Low
222.00
Averages
317.10
High
380.00
Current: 225.280
Low
222.00
Averages
317.10
High
380.00
Baird
Outperform -> NULL
downgrade
$319 -> $283
2026-01-08
Reason
Baird
Price Target
$319 -> $283
AI Analysis
2026-01-08
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Veeva to $283 from $319 and keeps an Outperform rating on the shares.
Truist
Jailendra Singh
Hold
to
Buy
upgrade
2026-01-08
Reason
Truist
Jailendra Singh
Price Target
2026-01-08
upgrade
Hold
to
Buy
Reason
Truist analyst Jailendra Singh upgraded Veeva to Buy from Hold.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VEEV
Unlock Now
Truist
Jailendra Singh
Hold
to
Buy
upgrade
$275
2026-01-08
Reason
Truist
Jailendra Singh
Price Target
$275
2026-01-08
upgrade
Hold
to
Buy
Reason
Truist analyst Jailendra Singh upgraded Veeva to Buy from Hold with a $275 price target. Market share shifts in the top 20 pharma have largely played out, with migration-related revenue impacts likely deferred beyond FY27, the analyst tells investors in a research note. Combined with strong execution in growth areas like Crossix and early AI traction, Veeva is positioned for durable growth and margin stability, making current valuations attractive from a risk/reward perspective, the firm argues.
Wells Fargo
Stan Berenshteyn
Overweight
maintain
$341 -> $333
2025-11-25
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$341 -> $333
2025-11-25
maintain
Overweight
Reason
Wells Fargo analyst Stan Berenshteyn lowered the firm's price target on Veeva to $333 from $341 and keeps an Overweight rating on the shares. The firm cites lower comparable multiples, offset somewhat by raised estimates. Despite the decremental optics from more CRM takeaways, Veeva's product-led growth narrative is strengthening with valuation near trough levels, Wells adds.
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data, and business consulting and is designed to meet the needs of its customers and the strategic business functions from research and development (R&D) through commercialization. Its four product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes, and partners across content management, training, quality management, assurance, and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. Veeva Data Cloud is a data platform comprised of connected reference data, deep data, and transaction data.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
